{"schema_version":"secwatch.filing_event.v1","accession":"0001628908-22-000138","form_type":"8-K","ticker":"EVH","cik":"0001628908","company_name":"Evolent Health, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.491311+00:00","generated_at":"2026-06-22T14:11:36.376154+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolent Health Q3 2022 revenue up 58.5% to $352.6M; net income $2.1M","bullets":["Revenue of $352.6M, +58.5% YoY; net income $2.1M (0.6% margin).","Adjusted EBITDA of $28.1M (8.0% margin), vs prior-year loss.","Total lives on platform 19.5M; EHS 2.1M, Clinical Solutions 17.4M.","Signed 3 new operating partnerships, including Molina Healthcare expansion and WA ACO for 2023 MSSP.","Dan McCarthy promoted to President; Kali Beyah appointed Chief People and Brand Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001628908-22-000138","json":"https://secwatch.observer/filing/0001628908-22-000138.json","markdown":"https://secwatch.observer/filing/0001628908-22-000138.md","text":"https://secwatch.observer/filing/0001628908-22-000138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628908/000162890822000138/0001628908-22-000138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628908/000162890822000138/evh-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T14:11:36.376154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5635d92dc833d58b3a319ef16500e39d13acb7a","claim":"Evolent Health, Inc. reported the quarter ended September 30, 2022 results: revenue $352.6 million, net income $2.1 million.","evidence_excerpt":"Quarter ended September 30, 2022: • Revenue of $352.6 million, an increase of $130.1 million, or 58.5%, from the three months ended September 30, 2021. • Net income attributable to common shareholders of Evolent Health, Inc. of $2.1 million resulting in a net income margin of 0.6%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628908/000162890822000138/0001628908-22-000138-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$352.6 million"},{"label":"Net income","value":"$2.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}